Next Article in Journal
The Hippo Signaling Pathway in Drug Resistance in Cancer
Next Article in Special Issue
Differentiated Thyroid Cancer: A Health Economic Review
Previous Article in Journal
A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer
Previous Article in Special Issue
Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study
 
 
Article

18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib

1
Department of Nuclear Medicine, University Hospital, LMU Munich, 81377 Munich, Germany
2
Department of Internal Medicine IV, University Hospital, LMU Munich, 81377 Munich, Germany
3
Comprehensive Cancer Center (CCC LMU), University Hospital, LMU Munich, 81377 Munich, Germany
4
Interdisciplinary Center for Thyroid Carcinoma (ISKUM), University Hospital, LMU Munich, 81377 Munich, Germany
5
Department of Radiology, University Hospital, LMU Munich, 81377 Munich, Germany
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(2), 317; https://doi.org/10.3390/cancers13020317
Received: 14 December 2020 / Revised: 11 January 2021 / Accepted: 14 January 2021 / Published: 16 January 2021
(This article belongs to the Special Issue Advances in the Diagnosis and Treatment of Thyroid Carcinoma)
In patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC), therapeutic options are limited. In the “Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT)”, Lenvatinib significantly prolonged the progression-free survival, resulting in a more frequent use in clinical practice for this patient group. Due to considerable side effects, an accurate assessment of response to treatment is crucial in these patients. Therefore, we aimed to improve treatment individualization and reduce unnecessary therapies by selecting patients who will most likely benefit from Lenvatinib treatment using 2-deoxy-2-[18F] fluoro-D-glucose positron-emission-tomography/computed-tomography.
Background: The tyrosine kinase inhibitor (TKI) Lenvatinib represents one of the most effective therapeutic options in patients with advanced radioiodine refractory differentiated thyroid carcinoma (DTC). We aimed to assess the role of 2-deoxy-2-[18F] fluoro-D-glucose positron-emission-tomography/computed-tomography (18F-FDG-PET/CT) in the monitoring of functional tumor response compared to morphological response. Methods: In 22 patients, a modified Positron Emission Tomography Response Criteria In Solid Tumors (mPERCIST) evaluation before treatment with Lenvatinib and at 3 and 6 month follow up was performed. Further PET-parameters and morphologic tumor response using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 were assessed and their prediction of progression-free survival (PFS) and disease-specific survival (DSS) was evaluated. Results: Most patients were rated stable in morphological evaluation and progressive using a metabolic response. All patients who responded to therapy through RECIST showed a decline in nearly all Positron Emission Tomography (PET)-parameters. For both time-points, non-responders according to mPERCIST showed significantly lower median PFS and DSS, whereas according to RECIST, only DSS was significantly lower. Conclusion: Tumor response assessment by 18F-FDG-PET outperforms morphological response assessment by CT in patients with advanced radioiodine refractory DTC treated with Lenvatinib, which seems to be correlated with clinical outcomes. View Full-Text
Keywords: differentiated thyroid cancer; radioiodine refractory; Lenvatinib; 18F-FDG-PET/CT differentiated thyroid cancer; radioiodine refractory; Lenvatinib; 18F-FDG-PET/CT
Show Figures

Figure 1

MDPI and ACS Style

Ahmaddy, F.; Burgard, C.; Beyer, L.; Koehler, V.F.; Bartenstein, P.; Fabritius, M.P.; Geyer, T.; Wenter, V.; Ilhan, H.; Spitzweg, C.; Todica, A. 18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib. Cancers 2021, 13, 317. https://doi.org/10.3390/cancers13020317

AMA Style

Ahmaddy F, Burgard C, Beyer L, Koehler VF, Bartenstein P, Fabritius MP, Geyer T, Wenter V, Ilhan H, Spitzweg C, Todica A. 18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib. Cancers. 2021; 13(2):317. https://doi.org/10.3390/cancers13020317

Chicago/Turabian Style

Ahmaddy, Freba, Caroline Burgard, Leonie Beyer, Viktoria Florentine Koehler, Peter Bartenstein, Matthias P. Fabritius, Thomas Geyer, Vera Wenter, Harun Ilhan, Christine Spitzweg, and Andrei Todica. 2021. "18F-FDG-PET/CT in Patients with Advanced, Radioiodine Refractory Thyroid Cancer Treated with Lenvatinib" Cancers 13, no. 2: 317. https://doi.org/10.3390/cancers13020317

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop